Intercept Pharmaceuticals (FRA:I4P) Deferred Tax : €0.0 Mil (TTM As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Intercept Pharmaceuticals's change in deferred tax for the three months ended in Sep. 2023 was €0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2023 was €0.0 Mil.

Intercept Pharmaceuticals Deferred Tax Historical Data

The historical data trend for Intercept Pharmaceuticals's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Deferred Tax Chart

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Deferred Tax

Get a 7-Day Free Trial

Intercept Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Intercept Pharmaceuticals Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Intercept Pharmaceuticals Deferred Tax Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (FRA:I4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (FRA:I4P) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

N/A

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Intercept Pharmaceuticals (FRA:I4P) Headlines

No Headlines